Baseline demographics and disease characteristics of patients included in analyses of PREMIER*
| Baseline characteristic | ADA+MTX (N=229) | ADA (N=205) | MTX (N=204) |
|---|---|---|---|
| Age (years) | 51.9±14.0 | 51.9±12.9 | 52.8±13.3 |
| Female, n (%) | 162 (70.7) | 156 (76.1) | 153 (75.0) |
| Race (white), n (%) | 218 (95.2) | 193 (94.1) | 191 (93.6) |
| Disease duration (years) | 0.7±0.8 | 0.7±0.8 | 0.8±0.9 |
| Rheumatoid factor positive, n (%) | 187 (83.9) | 179 (88.6) | 172 (86.0) |
| Previous DMARD use, n (%) | 72 (31.4) | 69 (33.7) | 61 (29.9) |
| Baseline corticosteroid use, n (%) | 82 (35.8) | 74 (36.1) | 68 (33.3) |
| SJC (66) | 21.3±11.5 | 21.7±10.4 | 22.2±12.0 |
| TJC (68) | 30.5±14.4 | 32.5±13.7 | 32.0±14.2 |
| DAS28(CRP) | 6.3±0.9 | 6.3±0.9 | 6.3±0.9 |
| HAQ-DI | 1.5±0.6 | 1.6±0.6 | 1.5±0.7 |
| CRP (mg/dl) | 4.0±4.2 | 3.8±3.6 | 4.0±4.1 |
| mTSS | 18.7±20.6 | 18.9±18.8 | 22.2±22.5 |
| JE | 11.4±12.8 | 11.5±11.4 | 13.8±13.7 |
| JSN | 7.3±9.4 | 7.4±8.8 | 8.4±10.8 |
| Employed, n (%)† | 109 (60.2) | 88 (52.1) | 99 (58.2) |
All values are mean±SD, unless otherwise indicated.
*Includes data from patients who completed 52 and/or 104 weeks of treatment, had at least one post-baseline DAS28(CRP), and underwent radiography at baseline and week 52 and/or 104.
†A total of 181, 169 and 170 patients from the ADA+MTX, ADA, and MTX groups, respectively, had employment data at baseline.
ADA, adalimumab; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; DAS28, 28-joint disease activity score; HAQ-DI, disability index of the health assessment questionnaire; JE, joint erosion; JSN, joint space narrowing; MTX, methotrexate; mTSS, modified total Sharp score; SJC, swollen joint count; TJC, tender joint count.